Who Exports Rituximab from India — 164 Suppliers Behind a $19.1M Market
India's rituximab export market is supplied by 164 active exporters who collectively shipped $19.1M across 1,215 shipments. DR.REDDY'S LABORATORIES LTD leads with a 41.5% market share, followed by RELIANCE LIFE SCIENCES PRIVATE LIMITED and DR REDDYS LABORATORIES LIMITED. The top 5 suppliers together control 87.1% of total export value, reflecting a concentrated market structure.
Top Rituximab Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading rituximab exporter from India, holding a 41.5% share of the $19.1M market across 1,215 shipments from 164 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, RELIANCE LIFE SCIENCES PRIVATE LIMITED, DR REDDYS LABORATORIES LIMITED, MEDWISE OVERSEAS PRIVATE LIMITED, HETERO BIOPHARMA LIMITED — collectively control 87.1% of total export value, indicating a highly concentrated market. Individual shares are: DR.REDDY'S LABORATORIES LTD (41.5%), RELIANCE LIFE SCIENCES PRIVATE LIMITED (21.4%), DR REDDYS LABORATORIES LIMITED (13.8%), MEDWISE OVERSEAS PRIVATE LIMITED (5.7%), HETERO BIOPHARMA LIMITED (4.7%).
Top Rituximab Exporters from India
Ranked by export value · 164 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD RITUXIMAB WCBWORKING CELL BANKQTY:09VIALSNET QTY:27 GMSRITUXIMAB WORKING CELL BANKRITUXIMAB WCB | $7.9M | 17 | 41.5% |
| 2 | RELIANCE LIFE SCIENCES PRIVATE LIMITED RITUXIMAB 500MG7000 QTY RITUXIMAB INJECTION 500MG5076 VIALS RITUXIMAB INJECTION 500MGRITU | $4.1M | 18 | 21.4% |
| 3 | DR REDDYS LABORATORIES LIMITED RITUXIMAB WCBWORKING CELL BANKQTY:09VIALSNET QTY:27 GMSRITUXIMAB WORKING CELL BANKRITUXIMAB WCB | $2.6M | 5 | 13.8% |
| 4 | MEDWISE OVERSEAS PRIVATE LIMITED RITUXIREL 500 MG ,RITUXIREL 100 MG , | $1.1M | 1 | 5.7% |
| 5 | HETERO BIOPHARMA LIMITED RITUXIMAB 500MG/50ML VIAL 1S MXRITUXIMAB 500MGRITUXIMABBULK | $901.0K | 4 | 4.7% |
| 6 | INVEX HEALTH PRIVATE LIMITED | $202.1K | 2 | 1.1% |
| 7 | INTAS PHARMACEUTICALS LIMITED | $158.4K | 4 | 0.8% |
| 8 | J.A. UNITED EXPORTS PRIVATE LIMITED | $122.3K | 4 | 0.6% |
| 9 | R.S. SURGIPHARM PRIVATE LIMITED RITUXIMAB INJECTION 500MGRITUXIMAB INJECTION 100MGRITUXIMAB INJECTION 500MG/50ML | $118.2K | 2 | 0.6% |
| 10 | RMPL PHARMA LLP RITUXIMAB INJECTION 500MGRITUXIMAB INJECTION 100MGRITUXIMAB INJECTION 500MG/50ML | $92.7K | 9 | 0.5% |
| 11 | PNT PHARMA | $86.7K | 1 | 0.5% |
| 12 | SANSKRUTI PHARMA REDDITUX 10MG/MLCONCENTRATE FOR SOLUTIONFOR INFUSIONREDDITUX 10MG/ML CONCENTRATE FOR SOLUTION FOR INFUSIONREDDITUX 500 MGRITUXIMAB | $71.6K | 3 | 0.4% |
| 13 | HEET HEALTHCARE PRIVATE LIMITED | $58.3K | 3 | 0.3% |
| 14 | DOSHI MEDICARE PRIVATE LIMITED | $55.6K | 5 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Rituximab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| DR. REDDY'S LABORATORIES LTD | Approved | Yes | Yes | Multiple | Facilities regularly audited by USFDA, EMA, WHO GMP, and others. |
| HETERO BIOPHARMA LIMITED | Approved | Yes | Yes | Multiple | Facilities inspected and approved by USFDA, WHO, and EMA. |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Manufacturing facilities comply with USFDA, WHO, and EMA standards. |
| RELIANCE LIFE SCIENCES PRIVATE LIMITED | Approved | Yes | Yes | Multiple | Facilities meet USFDA, WHO, and EMA regulatory requirements. |
| DR REDDYS LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Regularly audited by USFDA, EMA, and WHO GMP. |
| MEDWISE OVERSEAS PRIVATE LIMITED | Not Listed | Yes | Yes | Not Listed | Complies with WHO and EU GMP standards. |
| INVEX HEALTH PRIVATE LIMITED | Not Listed | Yes | Yes | Not Listed | Holds WHO and EU GMP certifications. |
| J.A. UNITED EXPORTS PRIVATE LIMITED | Not Listed | Yes | Yes | Not Listed | Certified under WHO and EU GMP guidelines. |
| R.S. SURGIPHARM PRIVATE LIMITED | Not Listed | Yes | Yes | Not Listed | Compliant with WHO and EU GMP standards. |
| RMPL PHARMA LLP | Not Listed | Yes | Yes | Not Listed | Holds WHO and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 10 leading Rituximab exporters from India. 5 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Rituximab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's bulk drug capital, is a central hub for active pharmaceutical ingredients (APIs) and biologics. The city's Genome Valley anchors R&D and biologics, while legacy industrial areas host APIs and intermediates. Hyderabad Pharma City, an integrated cluster, is progressing to consolidate APIs, formulations, and support services with common utilities and effluent treatment plants. This ecosystem supports companies like Dr. Reddy's Laboratories Ltd., which accounted for 41.5% of Rituximab exports, totaling $7.9 million.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. This region hosts numerous manufacturing facilities specializing in finished dosage forms, including injectables and biosimilars. Companies such as Intas Pharmaceuticals Limited, contributing 0.8% to Rituximab exports, benefit from the well-established infrastructure and skilled workforce in this area.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a strategic export gateway for pharmaceutical products. Mumbai, being the headquarters for major pharmaceutical companies like Cipla, facilitates global distribution networks. The proximity to major ports enhances the export efficiency of companies operating in this region.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, initially attracting companies through tax incentives. The region houses over 3,120 factories, including those of major pharmaceutical firms, contributing to an annual turnover of Rs 60,000 crore. Despite the phasing out of initial tax benefits, the established infrastructure and ecosystem continue to support pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: While Dr. Reddy's Laboratories Ltd. leads with 41.5% of Rituximab exports, consider engaging with other suppliers like Reliance Life Sciences Private Limited (21.4%) and Hetero Biopharma Limited (4.7%) to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad's expertise in biologics for API sourcing and Ahmedabad-Vadodara's capabilities in formulations to optimize production processes.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to enhance distribution efficiency and reduce lead times.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Rituximab exporters from India
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's acquires Mayne Pharma's U.S. generic portfolio
Dr. Reddy's Laboratories entered into a definitive agreement to acquire Mayne Pharma's U.S. generic prescription product portfolio, including approximately 45 commercial products, four pipeline products, and 40 approved non-marketed products. - IMPACT: This acquisition is expected to enhance Dr. Reddy's product offerings in the U.S. market, potentially increasing resources for Rituximab exports.
Impact: This acquisition is expected to enhance Dr. Reddy's product offerings in the U.S. market, potentially increasing resources for Rituximab exports.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's acquires India trademarks for two HRT drugs
Dr. Reddy's Laboratories acquired the India trademarks for specialty brands Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited for $32.15 million, strengthening its gynecology portfolio in India. - IMPACT: This acquisition may bolster Dr. Reddy's domestic market presence, potentially influencing its global export strategies, including Rituximab.
Impact: This acquisition may bolster Dr. Reddy's domestic market presence, potentially influencing its global export strategies, including Rituximab.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's sells Louisiana subsidiary
Dr. Reddy's Laboratories Inc., USA, completed the sale of all issued and outstanding membership interests in its wholly owned subsidiary, Dr. Reddy's Laboratories Louisiana LLC, including the manufacturing facility located in Shreveport, Louisiana. - IMPACT: The divestiture may streamline Dr. Reddy's operations, potentially affecting its manufacturing and export capacities, including Rituximab.
Impact: The divestiture may streamline Dr. Reddy's operations, potentially affecting its manufacturing and export capacities, including Rituximab.
Common Questions — Rituximab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which rituximab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 64 recorded shipments worth $7.9M. RELIANCE LIFE SCIENCES PRIVATE LIMITED (102 shipments) and DR REDDYS LABORATORIES LIMITED (11 shipments) are also established high-volume exporters.
Q How many rituximab manufacturers are there in India?
India has 164 active rituximab exporters with a combined export market of $19.1M across 1,215 shipments to 104 countries. The top 5 suppliers hold 87.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for rituximab from India?
Average FOB unit price: $104.42 per unit, ranging from $0.01 to $2534.33. Average shipment value: $15.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 164 verified Indian exporters of Rituximab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,215 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 104 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,215 Verified Shipments
164 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists